A study involving 150,000 participants in Sweden found that individuals using medications to control their symptoms face a diminished risk of suicidal behavior, criminal charges, substance misuse, accidental injuries, and traffic incidents. Prior research supports this, yet the team behind this latest study claims it’s the most substantial evidence available to date.

“This represents the best methodology, akin to a randomized trial,” states Zheng Chang from the Karolinska Institute in Sweden.

When considering medications for ADHD management, the wider impact of avoiding these treatments might not be fully recognized, according to Samuelle Cortese from the University of Southampton, UK. He suggests parents often become preoccupied with immediate academic challenges but should also consider potential long-term outcomes.

“Neglecting ADHD can be risky,” he emphasizes. “Current evidence indicates that treatment lowers these risks.”

Individuals with ADHD frequently struggle with attention and exhibit impulsivity. Randomized controlled trials indicate that medications are effective in handling immediate symptoms.

Such trials involve randomly assigning individuals to either receive treatment or not, regarded as the gold standard in medical research. However, no randomized studies have yet evaluated the broader effects of ADHD medications, forcing researchers to rely on observational studies, which do not definitively prove that medication leads to noted behavioral changes.

Recently, Chang, Cortese, and their team executed a method known as target trial emulation. They utilized Swedish medical and legal records to compare patients who began ADHD medication promptly after diagnosis with those who delayed.

The results indicated that those using ADHD medications were 25% less likely to face criminal charges or experience substance problems. They also recorded a 16% reduction in traffic accident involvement, a 15% lower risk for suicide attempts, and a 4% decrease in accidental injuries.

“Understanding if medication can influence daily life beyond mere symptom alleviation is invaluable,” stated Adam Guastella during an interview with the UK Science Media Centre at the University of Sydney, Australia. “This knowledge will also assist governments and policymakers in recognizing the potential societal benefits of comprehensive care, including mental health and criminal justice outcomes.”

If you need someone to talk to, please reach out: UK Samaritans: 116123 (samaritans.org); US 988 Suicide & Crisis Lifeline: 988 (988lifeline.org). Find more helplines at bit.ly/suicidehelplines for other regions.